| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.86B | +21.3% |
| Gross profit | ¥0.73B | — |
| Operating income | ¥0.39B | — |
| Net income | ¥0.30B | +481.4% |
| Gross margin | 25.5% | Net margin 10.6% |
| Revenue Q/Q | -4.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥2.13B | 74.5% |
| R&D | ¥0.27B | 9.3% |
| SG&A | ¥0.18B | 6.3% |
| Tax & other | ¥0.09B | 3.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
阿特斯 ・ 百利天恒 ・ 芯原股份 ・ 中芯国际 ・ 特锐德 ・ 神州泰岳 ・ 乐普医疗 ・ 南风股份 ・ 探路者 ・ 莱美药业 ・ 汉威科技 ・ 天海防务
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies